Compare Allegion PLC (ALLE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allegion PLC vs Recursion Pharmaceuticals Inc — how do they compare? Allegion PLC trades at $165.68 (market cap $14.32B), while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: Allegion PLC is far larger — about 7.9× Recursion Pharmaceuticals Inc's market cap, and Allegion PLC pays a 1.26% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ALLE | RXRX | |
|---|---|---|
Market Cap | $14.32B | $1.81B |
Sector | Industrials | Health |
52-Week High | $179.77 | $6.79 |
52-Week Low | $125.65 | $2.84 |
Enterprise Value | $16.03B | $1.33B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALLE trades at $165.9, up 0.22% today, near its consensus price target of $156. The stock shows bullish technical signals with strong moving average support, though RSI levels indicate potential overbought conditions. Fundamentally, the company reported robust Q2 2026 results with EPS of $2.40 beating estimates, driven by 13% revenue growth and margin expansion in the Americas segment. Recent news highlights raised full-year guidance and institutional buying interest.
Outlook remains positive given earnings momentum and raised guidance, but risks include reliance on Americas growth and cost pressures. Analyst sentiment is mixed with a Hold consensus, yet the stock's current price above the target suggests limited near-term upside. Execution on international growth and margin sustainability are key for further appreciation.
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
